Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors by Palisse, Adeline, Cheung, Tony, Blokhuis, Aileen, Cogswell, Thomas, Martins, Bruna S, Riemens, Rick, Schellekens, Rick, Battocchio, Giovanni, Jansen, Chimed, Cottee, Matthew A, Ornell, Kimberly, Sacchetto, Claudia, Leon, Leonardo, van Hoek-Emmelot, Maaike, Bostock, Mark, Brauer, Brooke Leann, Beaumont, Kevin, Lucas, Simon C C, Ahmed, Samiyah, Blackwell, J Henry, Börjesson, Ulf, Gohlke, Andrea, Gramatikov, Iva Monique T, Hargreaves, David, van Hoeven, Vera, Kantae, Vasudev, Kupcova, Lea, Milbradt, Alexander G, Seneviratne, Uthpala, Su, Nancy, Vales, John, Wang, Haiyun, White, Michael J, Kinzel, Olaf

Get full text

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies by Kaptein, Allard, de Bruin, Gerjan, Emmelot-van Hoek, Maaike, van de Kar, Bas, de Jong, Anouk, Gulrajani, Michael, Demont, Dennis, Covey, Todd, Mittag, Diana, Barf, Tjeerd

Get full text

Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors by Hoogenboom, Niels, Demont, Dennis, de Zwart, Edwin, Verkaik, Saskia, Emmelot, Maaike, van de Kar, Bas, Kaptein, Allard, Barf, Tjeerd

Get full text

Discovery of quinoline-based irreversible BTK inhibitors by de Bruin, Gerjan, Demont, Dennis, de Zwart, Edwin, Verkaik, Saskia, Hoogenboom, Niels, van de Kar, Bas, van Lith, Bart, Emmelot- van Hoek, Maaike, Gulrajani, Michael, Covey, Todd, Kaptein, Allard, Barf, Tjeerd

Get full text

Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity by Kaptein, Allard, Podoll, Terry, Bruin, Gerjan de, Hoek, Maaike Emmelot-van, Jong, Anouk de, Lith, Bart van, Hoogenboom, Niels, Barf, Tjeerd, Ware, Joseph, Slatter, J. Greg

Get full text

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies by Kaptein, Allard, de Bruin, Gerjan, Hoek, Maaike Emmelot-van, van de Kar, Bas, de Jong, Anouk, Gulrajani, Michael, Demont, Dennis, Covey, Todd, Mittag, Diana, Barf, Tjeerd

Get full text

Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors by Podoll, Terry, Pearson, Paul G., Kaptein, Allard, Evarts, Jerry, de Bruin, Gerjan, Emmelot-van Hoek, Maaike, de Jong, Anouk, van Lith, Bart, Sun, Hao, Byard, Stephen, Fretland, Adrian, Hoogenboom, Niels, Barf, Tjeerd, Slatter, J. Greg

Get full text